AIM ImmunoTech Inc. (AIM) - Dana dhuwit diétung saben saham

AIM ImmunoTech relies on Ampligen patents that restrict competitor access under strict FDA oversight. The primary drivers are drug trials for cancer and long COVID aimed at global market entry. High R&D expenses for fatigue treatment are hindering scaling. Cash per share confirms liquidity, with the metric holding at 0.17.
Rincian analitis perusahaan AIM ImmunoTech

For the biotechnology sector company AIM ImmunoTech (AIM), this indicator determines the financial reserve per share required for the development of the Ampligen drug. The metric measures the volume of liquidity available to cover operating expenses without incurring external debt. By analyzing the cash per share forecast, an investor assesses the company's solvency during the clinical trial period. The stability of this indicator minimizes bankruptcy risks. This capital reserve confirms the fundamental resilience of the business within the immunology market.